- Report
- April 2025
- 290 Pages
Global
From €5331EUR$5,850USD£4,554GBP
- Report
- April 2025
- 175 Pages
Global
From €4092EUR$4,490USD£3,495GBP
- Report
- May 2024
- 130 Pages
Global
From €5923EUR$6,499USD£5,059GBP
- Report
- October 2024
- 318 Pages
Global
From €7245EUR$7,950USD£6,188GBP
- Report
- February 2022
- 36 Pages
Global
From €1823EUR$2,000USD£1,557GBP
- Report
- April 2025
- 50 Pages
Global
From €2415EUR$2,650USD£2,063GBP
- Report
- November 2021
- 844 Pages
Global
From €4557EUR$5,000USD£3,892GBP
Ropinirole is a centrally-acting dopamine agonist used to treat Parkinson's disease and restless legs syndrome. It is a non-ergoline dopamine agonist, meaning it does not contain the ergot alkaloid found in some other dopamine agonists. Ropinirole works by stimulating dopamine receptors in the brain, which helps to reduce the symptoms of Parkinson's disease and restless legs syndrome. It is available in both immediate-release and extended-release formulations.
Ropinirole is marketed by several pharmaceutical companies, including GlaxoSmithKline, Sun Pharmaceuticals, and Mylan. It is also available as a generic drug in some countries. It is available in tablet, capsule, and oral solution forms.
In the market for central nervous system drugs, Ropinirole is a popular choice for treating Parkinson's disease and restless legs syndrome. It is well-tolerated and has a low risk of side effects. It is also relatively inexpensive compared to other dopamine agonists.
Companies in the Ropinirole market include GlaxoSmithKline, Sun Pharmaceuticals, Mylan, Teva Pharmaceuticals, and Accord Healthcare. Show Less Read more